Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Welcia Holdings Co., Ltd. (3141:JPX), powered by AI.
Welcia Holdings Co., Ltd. is currently trading at ¥3,160. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Welcia Holdings Co., Ltd. on Alpha Lenz.
Welcia Holdings Co., Ltd.'s P/E ratio is 43.8.
“Welcia Holdings Co., Ltd. trades at a P/E of 43.8 (premium valuation) with modest ROE of 6.2%.”
Ask for details →Welcia Holdings Co., Ltd. is a prominent entity in Japan's retail sector, primarily focused on operating a chain of drugstores. The company's primary function is to provide a comprehensive range of health, wellness, and beauty products, catering to diverse consumer needs. Welcia is well-regarded for offering pharmaceuticals, over-the-counter medications, cosmetics, groceries, and daily essentials. One of its notable features is the integration of prescription services, enabling customers to fulfill their healthcare needs under one roof. The company serves various consumer segments, including individuals seeking medical supplies and personal care products. Welcia Holdings plays a crucial role in the retail industry by continuously expanding its footprint through strategic openings and acquisitions, thus enhancing its accessibility and market reach. Additionally, it emphasizes customer service excellence and convenience, forming a vital part of Japan’s robust drugstore sector. Headquartered in Tokyo, Welcia Holdings is instrumental in shaping retail pharmacy trends across the region, significantly impacting how consumers interact with health and beauty markets.
“Welcia Holdings Co., Ltd. trades at a P/E of 43.8 (premium valuation) with modest ROE of 6.2%.”
Ask for details →Welcia Holdings Co., Ltd. (ticker: 3141) is a company listed on JPX in the Healthcare sector (Pharmaceutical Retailers). It has approximately 16,611 employees. Market cap is $654.4B.
The current price is 3,160 with a P/E ratio of 43.75x and P/B of 2.63x.
ROE is 6.15% and operating margin is 2.83%. Annual revenue is $1.3T.